

ANTIBACTERIAL RESISTANCE PATTERN OF PSEUDOMONAS AERUGINOSA CO-ISOLATED WITH OTHER AEROBIC BACTERIA FROM BURN WOUNDS IN TERTIARY CARE HOSPITALKalpana Sadawarte¹, Sneha Dadarya², Tukaram Prabhu K³**HOW TO CITE THIS ARTICLE:**

Kalpana Sadawarte, Sneha Dadarya, Tukaram Prabhu K. "Antibacterial Resistance Pattern of Pseudomonas Aeruginosa Co-Isolated with other Aerobic Bacteria from Burn Wounds in Tertiary Care Hospital". Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 02, January 13; Page: 464-468, DOI:10.14260/jemds/2014/1850

ABSTRACT: The antibacterial resistance pattern of 118 isolates from burn wounds in patients with thermal burns showing growth of *Pseudomonas aeruginosa* mixed with other aerobic bacteria over a period of two years (January 2009-December 2010) were studied. *Pseudomonas aeruginosa* was found to be mixed with *Klebsiella pneumoniae* 63 (53.38%) the most followed by *Escherichia coli* 27 (22.88%) and other aerobic isolates. *Pseudomonas aeruginosa* was found to be highly resistant to Ceftazidime (72.88%) and least to Imipenem (9.32%). *Klebsiella pneumoniae* was found to be most resistant to Ampicillin (100%) and least to Amikacin (23.72%). Antibiotic susceptibility testing was performed for the other isolates as well.

KEY WORDS: Burn Wound infection, *Pseudomonas aeruginosa*, Antibiotic resistance.

INTRODUCTION: The colonization and infection in burn victims is a problem in their management as burn wounds are susceptible to infection¹. Major cause behind mortality and morbidity in burn patients who are hospitalized is infection². The determination of antimicrobial sensitivity pattern, changes in dominant microbial flora and burn wound microbial colonization is very important³. Due to the longer hospital stay, larger suitable burn site and rich source for bacterial multiplication than surgical wounds helps in survival of organisms⁴. There is a lot of change in the pattern of bacterial flora with respect to the hospital environment and during healing period in wound⁵. The antibiotic susceptibility pattern helps in selection of proper empirical treatment in a hospital beforehand. In the present retrospective study an attempt has been made to analyze and compile the pattern of bacterial infection in the burn wounds and their antibiotic susceptibility pattern to benefit the patient.

MATERIAL AND METHODS: This retrospective study was conducted between January 2009 to December 2010 in a 750-bedded tertiary care hospital. 118 isolates which showed growth of *Pseudomonas aeruginosa* mixed with other aerobic isolates were included in the present study. The ones without the growth of *Pseudomonas* spp were excluded.

Burn wound swabs/specimens/pus were collected and sent to the laboratory following standard precautions and protocols for the processing. The samples were inoculated on blood agar, MacConkey's agar and chocolate agar, incubated at 37°C overnight aerobically⁶.

Over the study period, 118 non-duplicate consecutive *P. aeruginosa* isolated from the burn specimens were identified by standard bacteriological methods⁷.

Antibiotic susceptibility testing was determined by disc diffusion method using Mueller-Hinton agar plates following standard method^{7,8}. The isolates were identified by culture, staining

ORIGINAL ARTICLE

and biochemical tests including oxidase, lactose and maltose fermentation, catalase and their antibiotic sensitivity determined using Kirby Bauer disc diffusion technique.^{7,8,9}

Following antibiotics were used as per Clinical and Laboratory Standard Institute (CLSI) guidelines⁹

For *Pseudomonas aeruginosa* - piperacillin [100mcg], piperacillin-tazobactam [100/10mcg], gentamicin [10mcg], tobramycin [10mcg], amikacin [30mcg], netilmicin [30mcg], ceftazidime [30mcg], imipenem [10mcg], cefepime [30mcg], aztreonam [30mcg], ciprofloxacin [5mcg] and cefotaxime [30mcg].

For Gram negative isolates gentamicin [10mcg], amikacin [30mcg], ceftazidime [30mcg], imipenem [10mcg], ciprofloxacin [5mcg], ampicillin [10mcg], amoxy-clav [20/10mcg], cefotaxime [30mcg], cotrimoxazole [1.25/23.75mcg], piperacillin [100mcg] and piperacillin-tazobactam [100/10mcg]

For *Staphylococcus aureus* cephoitin [30mcg], erythromycin [15mcg], penicillin [10U], ciprofloxacin [5mcg], vancomycin [30mcg] ampicillin [10mcg], amoxy-clav [20/10mcg], cotrimoxazole [1.25/23.75mcg], cephoitin [30mcg] and cephalothin [30mcg].

RESULTS: In the present study, during a period of two years 118 specimen which showed multiple isolates along with *Pseudomonas aeruginosa* were included in this study. Along with *Pseudomonas aeruginosa* the other aerobic isolates included 63 (53.38%) *Klebsiella pneumoniae* species which was found to be most common followed by *E coli* 27 (22.88%), *Staphylococcus aureus* 20 (16.94%), *Proteus vulgaris* 05 (4.23%) and *Acinetobacter* species 03 (2.54%). [Table I]

Most of the *Pseudomonas aeruginosa* isolates were resistant to cephalosporins (ceftazidime - 72.88%, cefotaxime-71.18%, cefepime-68.64%) and least to Imipenem (9.32%). [Table II]

Staphylococcus aureus was found to be most resistant to ampicillin (85%) followed by penicillin (75%) and cephalothin (70%). Cephoitin was used to test for methicillin resistance and 60% of the isolates were resistant and none of the isolates were resistant to vancomycin. [Table III]

The Gram negative aerobic isolates found to be most resistant to ampicillin 100%, 88.88%, 80% for *Klebsiella pneumoniae*, *E coli* and *P vulgaris* respectively.

Klebsiella species were found to be less resistant to Amikacin (63.49%) and Ciprofloxacin (42.85%).

Similarly *E. coli* was found to be less resistant to amikacin 62.96% and ciprofloxacin 59.25%, whereas 20% of *Proteus vulgaris* were resistant to amikacin and ciprofloxacin.

Piperacillin-tazobactam, Amikacin, Imipenem (all 66.66%) was determined to be more effective against *Acinetobacter* species. All the isolates of *Acinetobacter* species showed resistance to cefotaxime and cotrimoxazole. [Table IV]

DISCUSSION: The aerobic isolates included in this study were *Pseudomonas aeruginosa* co-isolated with various aerobic gram positive and gram negative isolates of which *Klebsiella pneumoniae* 63 (53.38%) was found to be most common followed by *E. coli* 27 (22.88%), *Staphylococcus aureus* 20 (16.94%), *Proteus vulgaris* 05 (4.23%) and *Acinetobacter* species 03 (2.54%).

Patients in age group of 15-35 years were predominant in the study, most of them were females. In the present study, all the *Pseudomonas aeruginosa* were co-isolated with other aerobic bacterial growth from burn cases as mentioned elsewhere¹¹. *Klebsiella pneumoniae* is predominant organism along with *Pseudomonas aeruginosa* in the present study in contrast to some other studies

ORIGINAL ARTICLE

which reports *Staphylococcus aureus* as predominant isolate ^{11, 12}. The moist environment (open wounds and use of antiseptics) helps *Pseudomonas* to survive which might be a reason behind their predominance in burn wards ¹³.

CONCLUSION: It was observed that *Pseudomonas aeruginosa* along with *Klebsiella pneumoniae* was the commonest isolate among the mixed bacterial isolate in burn wound cases and it showed multidrug resistance. In conclusion, present observations seem to be helpful in providing useful guidelines for choosing effective therapy against isolates from burn patients and decrease mortality and morbidity. Also to be taken into consideration is the fact the most of these infections involve more than one bacterial species. In-vitro antibiotic testing of burn wound isolates prior its use is helpful in management of bacterial infection and prevents development of multidrug resistance in pathogens.

REFERENCES:

1. Macedo JLS, Santos JB. Bacterial and fungal colonization of burn wounds. *Mem Inst Oswaldo Cruz* 2005; 100: 535-539.
2. Mc Manus A.T., Mason A.D.jr, McManus W.F., Pruitt B.A, Jr: A decade of reduced Gram -negative infections and mortality improved isolation of burned patients. *Arch.Surg.*, 1994; 129: 1306-1309.
3. Coker AO. Bacteriology of burns at the Lagos university teaching hospital. *West African Journal of Medicine* 1983; 2:53-258
4. Agnihotri N, Gupta V, Joshi RM., Aerobic bacterial isolate from burn wound infections and their antibiograms - a five - year study. *Burns* 2004; 30: 241-243.
5. Kumar V., Bhatnagar SK., Singh AK., Kumar S., Mishra RK. Burn Wound Infection: A study of 50 cases with special reference to antibiotic resistance. *Indian Journal of Bio Research* 2001; 46: 66-69.
6. Forbes BA, Sahm DF, Weissfeld AS. *Bailey and Scott's Diagnostic Microbiology*. 11th edition, Mosby, 2002
7. Gilligan PH. *Pseudomonas aeruginosa* and *Burkholderia*. In: Murray PR, Baron EJ, Pfaller AA, et al, eds. *Manual of Clinical Microbiology*, 6th Sub ed. Pp. 509-19, Washington DC, American Society for Microbiology, 1995.
8. Bauer AN, Kirby WMM, Sherris J, et al. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol*, 1966; 45: 493-6.
9. Clinical and Laboratory Standard Institute (CLSI) guidelines. Performance standards for antimicrobial susceptibility testing, M-100-S21, Vol 31 No.1, 2011.
10. Zorgani A., Zaidi M., Ranka R., Shahen A.:The pattern and outcome of septicaemia in a burns intensive care unit. *Ann.Burns Diasters*, 2002;15: 179-182.
11. Donati I, Scammazo F, Gervasoni M, Magliano A, Stankov B, Frascini F. Infection and antibiotic therapy in 4000 burned patients treated in Milan, Italy, between 1976 and 1988. *Burns* 1993; 19: 345-348
12. Revathi G, Puri J, Jain BK. Bacteriology of burns. *Burns*, 1998; 24: 347-349.
13. Atoyebi OA, Sowemimo GOA, Odugbemi T. Bacterial flora of burn wounds in Lagos, Nigeria: a prospective study. *Burns* 1992; 18: 448-451.

ORIGINAL ARTICLE

S.No	Organism	No. (n=118)	Percentage
1.	Staphylococcus aureus	20	16.94 %
2.	Klebsiella pneumoniae	63	53.38 %
3.	Escherichia coli	27	22.88 %
4.	Proteus vulgaris	05	4.23 %
5.	Acinetobacter species	03	2.54 %
	Total	118	

Table 1: Number of Isolates mixed with Pseudomonas (n = 118)

Antibiotic	No. (n=118)	Percentage
Piperacillin	55	46.61 %
Piperacillin tazobactam	38	32.20 %
Ceftazidime	86	72.88 %
Ciprofloxacin	52	44.06 %
Imipenem	11	9.32 %
Cefotaxime	84	71.18 %
Gentamicin	49	41.52 %
Amikacin	28	23.72 %
Tobramycin	60	50.84 %
Netilmicin	54	45.76 %
Aztreonam	39	33.05 %
Cefepime	81	68.64 %

Table 2: Antibiotic resistance pattern of Pseudomonas species

Antibiotic	No. (n=20) (Percentage)
Penicillin	15 (75 %)
Ampicillin	17 (85 %)
Erythromycin	10 (50 %)
Cephalothin	14 (70 %)
Cephoxitin	12 (60 %)
Vancomycin	00 (0 %)
Ciprofloxacin	10 (50 %)
Amoxy- Clav	09 (45 %)
Cotrimoxazole	13 (65 %)

Table 3: Antimicrobial resistance pattern of Staphylococcus aureus

Antibiotic	Klebsiella pneumoniae		E coli		Proteus vulgaris		Acinetobacter spp	
	No. (n=63)	Percent of resistant strains	No. (n=27)	Percent of resistant strains	No. (n=05)	Percent of resistant strains	No. (n=03)	Percent of resistant strains
Ampicillin	63	100 %	24	88.88 %	4	80 %	--	--
Amox-clav	53	84.12 %	21	77.77 %	3	60 %	--	--
Cotrimoxazole	53	84.12 %	21	77.77 %	4	80 %	3	100 %
Ciprofloxacin	27	42.85 %	16	59.25 %	1	20 %	2	66.66 %
Cefotaxime	50	79.36 %	22	81.48 %	2	40 %	3	100 %
Gentamicin	45	71.42 %	19	70.37 %	3	60 %	2	66.66 %
Amikacin	40	63.49 %	17	62.96 %	1	20 %	1	33.33 %
Piperacillin	--	--	--	--	--	--	2	66.66 %
Piperacillin tazobactam	--	--	--	--	--	--	1	33.33 %
Ceftazidime	--	--	--	--	--	--	2	66.66 %
Imipenem	--	--	--	--	--	--	1	33.33 %

Table 4: Resistance pattern of Gram negative bacteria

AUTHORS:

1. Kalpana Sadawarte
2. Sneha Dadarya
3. Tukaram Prabhu K.

PARTICULARS OF CONTRIBUTORS:

1. Professor, Department of Microbiology, People's College of Medical Sciences & Research Centre, Bhopal.
2. Tutor, Department of Microbiology, People's College of Medical Sciences & Research Centre, Bhopal.
3. Assistant Professor, Department of Microbiology, People's College of Medical Sciences & Research Centre, Bhopal.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Kalpana Sadawarte,
Professor,
Department of Microbiology,
People's College of Medical Sciences & Research
Centre, By-Pass Road, Bhanpur,
Bhopal – 462037 (M.P.)
Email- drkalpanasadawarte@gmail.com

Date of Submission: 09/12/2013.
Date of Peer Review: 10/12/2013.
Date of Acceptance: 23/12/2013.
Date of Publishing: 10/01/2014